An Interspecific Nicotiana Hybrid as a Useful and Cost-Effective Platform for Production of Animal Vaccines
Open Access
- 23 April 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4), e35688
- https://doi.org/10.1371/journal.pone.0035688
Abstract
The use of transgenic plants to produce novel products has great biotechnological potential as the relatively inexpensive inputs of light, water, and nutrients are utilised in return for potentially valuable bioactive metabolites, diagnostic proteins and vaccines. Extensive research is ongoing in this area internationally with the aim of producing plant-made vaccines of importance for both animals and humans. Vaccine purification is generally regarded as being integral to the preparation of safe and effective vaccines for use in humans. However, the use of crude plant extracts for animal immunisation may enable plant-made vaccines to become a cost-effective and efficacious approach to safely immunise large numbers of farm animals against diseases such as avian influenza. Since the technology associated with genetic transformation and large-scale propagation is very well established in Nicotiana, the genus has attributes well-suited for the production of plant-made vaccines. However the presence of potentially toxic alkaloids in Nicotiana extracts impedes their use as crude vaccine preparations. In the current study we describe a Nicotiana tabacum and N. glauca hybrid that expresses the HA glycoprotein of influenza A in its leaves but does not synthesize alkaloids. We demonstrate that injection with crude leaf extracts from these interspecific hybrid plants is a safe and effective approach for immunising mice. Moreover, this antigen-producing alkaloid-free, transgenic interspecific hybrid is vigorous, with a high capacity for vegetative shoot regeneration after harvesting. These plants are easily propagated by vegetative cuttings and have the added benefit of not producing viable pollen, thus reducing potential problems associated with bio-containment. Hence, these Nicotiana hybrids provide an advantageous production platform for partially purified, plant-made vaccines which may be particularly well suited for use in veterinary immunization programs.Keywords
This publication has 61 references indexed in Scilit:
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentVirology Journal, 2010
- Clustered Transcription Factor Genes Regulate Nicotine Biosynthesis in TobaccoTHE PLANT CELL ONLINE, 2010
- Tobacco, a highly efficient green bioreactor for production of therapeutic proteinsBiotechnology Advances, 2010
- Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine LicensureClinical and Vaccine Immunology, 2009
- Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against InfluenzaClinical and Vaccine Immunology, 2006
- Nicotine's Defensive Function in NaturePLoS Biology, 2004
- NewAgrobacterium helper plasmids for gene transfer to plantsTransgenic Research, 1993
- Mechanism of damage-induced alkaloid production in wild tobaccoJournal of Chemical Ecology, 1989
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972